# Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results

> **NCT05736978** · PHASE2 · RECRUITING · sponsor: **Shanghai Tong Ren Hospital** · enrollment: 58 (estimated)

## Conditions studied

- AML
- MRD

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Venetoclax
- **DRUG:** Selinexor

## Key facts

- **NCT ID:** NCT05736978
- **Lead sponsor:** Shanghai Tong Ren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-31
- **Primary completion:** 2025-03-01
- **Final completion:** 2027-03-15
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2023-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05736978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05736978, "Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05736978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*